Clean Cells Buys Anaquant
Clean Cells is expanding its biopharma quality-control platform with mass-spectrometry expertise.
Biopharma infrastructure is not always headline-grabbing, but it is where many advanced therapies either scale or get stuck. Clean Cells’ acquisition of Anaquant strengthens that back-end layer.
What happened
Clean Cells acquired Anaquant, a French contract research organisation specialising in mass-spectrometry-based protein quantification and identification. Financial terms were not disclosed.
The deal expands Clean Cells’ analytical capabilities for biopharma quality control, regulatory readiness and GMP testing. Anaquant’s expertise is especially relevant for measuring and identifying proteins, which is a critical task in biologics development and manufacturing.
Why it matters
As therapies become more complex, quality control becomes more important. Biologics, cell therapies and advanced medicines need detailed analytical testing to prove consistency, safety and regulatory compliance.
This acquisition is a life-sciences infrastructure signal. Clean Cells is not simply buying more capacity; it is adding a specialised analytical layer that can support customers through development, manufacturing and regulatory review.
The bigger picture
The biotech market is under pressure, but picks-and-shovels providers can still be attractive. Drug developers need reliable testing, manufacturing support and compliance infrastructure regardless of which therapeutic area is fashionable. Clean Cells buying Anaquant shows that life-sciences infrastructure companies are using M&A to deepen technical capabilities as the sector becomes more data-heavy and regulation-intensive.